West Branch Capital’s Exact Sciences EXAS Stock Holding History

West Branch Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	-$45	–	573
2024 Q3	$45	Buy	+1	New	+$56	﹤0.01%	587

Other funds holding EXAS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

West Branch Capital's EXAS Position: Q4 2024 in Review

West Branch Capital sold out of Exact Sciences (EXAS) in Q4 2024, closing a stake of 1 share — an estimated $45 sold.

West Branch Capital first reported a position in EXAS in Q3 2024 and held it in 1 quarter. The position peaked at $45 in Q3 2024. 593 funds tracked by Wall St. Rank hold EXAS as of Q4 2024.

West Branch Capital reported no remaining Exact Sciences position as of Q4 2024 after selling out during the quarter.
West Branch Capital sold 1 Exact Sciences share in Q4 2024, an estimated $45.
West Branch Capital first reported a position in Exact Sciences in Q3 2024 and held it in 1 quarter.
West Branch Capital's Exact Sciences position peaked at $45 in Q3 2024.
593 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2024.

Based on West Branch Capital's 13F filing for Q4 2024, filed 17 Jan 2025.